← feed

Is NCT02867735 results overdue?

Yes — results are overdue. Primary completion was 2018-02-15; the FDAAA-801 reporting deadline (2019-02-15) passed 2729 days ago and no results are posted on ClinicalTrials.gov.

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema

NCT IDNCT02867735 ↗
SponsorNovartis Pharmaceuticals (INDUSTRY)
Public issuerNOVARTIS AG — NVS (CIK 0001114448) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2018-02-15 (ACTUAL)
Reporting deadline2019-02-15 (completion + 365d)
Days overdue2729
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 b1b9692f725453d3… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02867735. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →